T4	intervention-participants 959 962	284
T5	control 967 974	placebo
T6	control-participants 980 983	287
T7	outcome 1002 1015	grade 3/4 AEs
T8	outcome 1036 1049	hyperglycemia
T9	outcome 1051 1058	grade 3
T10	outcome 1067 1074	grade 4
T11	outcome 1083 1087	rash
T12	outcome 1089 1096	grade 3
T13	outcome 1109 1117	diarrhea
T14	outcome 1119 1126	grade 3
T15	outcome 1135 1176	Median time to onset of grade ≥3 toxicity
T16	outcome 1449 1458	incidence
T18	iv-bin-percent 1471 1476	26.7%
T19	cv-bin-percent 1484 1489	64.1%
T20	outcome 1495 1511	severity of rash
T21	iv-bin-percent 1522 1527	11.6%
T22	cv-bin-percent 1535 1540	22.7%
T23	outcome 1577 1613	Discontinuations due to grade ≥3 AEs
T24	iv-bin-percent 1675 1679	7.9%
T25	cv-bin-percent 1687 1692	18.1%
T26	outcome 1790 1822	Median progression-free survival
T27	iv-cont-median 1842 1846	12.5
T28	iv-cont-median 1851 1861	9.6 months
T29	cv-cont-median 1953 1963	5.8 months
T1	intervention 98 139	PI3K inhibitor alpelisib plus fulvestrant
T2	outcome 1248 1252	rash
T3	outcome 1269 1277	diarrhea
T17	outcome 1460 1469	any grade
T30	outcome 1513 1520	grade 3
T31	outcome 1978 2000	Hyperglycemia and rash
T32	outcome 2228 2245	severe toxicities
